Open AccessAssociation of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan
Author(s) -
MuChi Chung,
PeirHaur Hung,
PoJen Hsiao,
Laing-You Wu,
ChaoHsiang Chang,
MingJu Wu,
JengJer Shieh,
ChiJung Chung
Publication year - 2021
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2021.35353
Subject(s) - medicine , incidence (geometry) , gout , hazard ratio , type 2 diabetes , population , cohort , type 2 diabetes mellitus , diabetes mellitus , cohort study , proportional hazards model , endocrinology , confidence interval , environmental health , optics , physics
Key Points Question Is the use of a sodium-glucose transport protein 2 (SGLT2) inhibitor for patients with type 2 diabetes associated with the incidence of gout? Findings In this Taiwan nationwide cohort study, there was a significant 11% risk reduction in the incidence of gout in 47 405 patients with type 2 diabetes who received an SGLT2 inhibitor compared with 47 405 propensity score–matched individuals receiving dipeptidyl peptidase 4 inhibitors, particularly for patients using dapagliflozin. The benefits of SGLT2 inhibitor use in patients with type 2 diabetes for a lower gout risk were not different across subgroups. Meaning The findings of this study suggest that use of SGLT2 inhibitors may help to decrease the incidence of gout in patients with type 2 diabetes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom